| 1.35 0 (0%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
NantHealth, Inc. functions as a healthcare information technology company with operations spanning the United States, Canada, and the United Kingdom. The company provides a range of software-as-a-service (SaaS) solutions aimed at enhancing healthcare delivery and administration. Among its offerings is Eviti, a SaaS-delivered clinical decision support platform that integrates clinical data, Medicare reimbursement details, and information on treatment toxicity. Eviti Connect leverages this platform to automate prior authorizations, assisting both insurers and healthcare providers in managing complex cancer treatments. Furthermore, Eviti Advisor enables medical professionals to consult Eviti's extensive repository of evidence-based guidelines and protocols when making therapeutic choices. NantHealth also offers NaviNet, a collection of SaaS tools designed to simplify communication and information exchange between healthcare payers and providers. This suite includes NaviNet Open, a collaborative platform for health plans and providers, and NaviNet AllPayer, which delivers critical patient details such as eligibility, benefits, and claim statuses for commercial, government, and Medicare plans directly to provider offices via the NaviNet portal. Beyond its core healthcare solutions, the company provides OpenNMS, an open-source network monitoring tool catering to enterprise-level infrastructures, and Quadris, a data analytics offering that encompasses multi-source data analysis, reporting, and expert professional services. Founded in 2010, the company was initially incorporated as Nant Health, LLC, before adopting its current name, NantHealth, Inc., in June 2016. It maintains its headquarters in Morrisville, North Carolina, and operates as a subsidiary of NantWorks, LLC.
Wed, 22 Jan 2025
NantHealth® Offers New NaviNet® AllPayer Subscription Packages, Now With Electronic Claim Submission - Business Wire
Mon, 11 Feb 2019
Baxter and NantHealth® Advance Digital Health Technology for Medical Devices in the Hospital ICU - BioSpace
Fri, 14 Sep 2018
Tailored Drug Cocktails Offer Hope to Kids with Aggressive Brain Tumors - Cancer Health
Thu, 05 Apr 2018
After More Than a Decade of Insane Growth, Is Apple's Revenue Finally Plateauing? - Yahoo Finance
Fri, 21 Jul 2017
NH Stock Price and Chart — NSE:NH - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|